Literature DB >> 23863525

Three-phase parathyroid 4-dimensional computed tomography initial experience: inexperienced readers have high accuracy and high interobserver agreement.

Ali R Sepahdari1, Michael W Yeh, David Rodrigues, Sarah N Khan, Avital Harari.   

Abstract

OBJECTIVE: Multiphase multidetector contrast-enhanced parathyroid CT (4-dimensional computed tomography [4D-CT]) is an emerging tool for evaluating patients with primary hyperparathyroidism. Our goal was to describe the initial performance of 2 inexperienced readers in interpretation of 4D-CT.
METHODS: Twenty-three subjects who received 4D-CT and successful surgical exploration were studied (14 initial and 9 repeat explorations; 15 single-gland disease and 8 multigland disease) A staff neuroradiologist prospectively interpreted all studies, and a neuroradiology fellow retrospectively interpreted all studies; their results were compared with the surgical findings for each side of the neck separately.
RESULTS: The prospective readings were 78% accurate overall, 97% accurate in the subset of single-gland disease cases, and 89% accurate in re-exploration cases. There was 91% concordance in interpretation between observers, with κ of 0.83.
CONCLUSIONS: Initial results after implementation of 4D-CT show high accuracy of interpretation for inexperienced observers, comparable to published data, and high interobserver agreement.

Entities:  

Mesh:

Year:  2013        PMID: 23863525     DOI: 10.1097/RCT.0b013e31828beb34

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  8 in total

1.  Effect of tumor volume on the enhancement pattern of parathyroid adenoma on parathyroid four-dimensional CT.

Authors:  Eun Kyoung Lee; Tae Jin Yun; Ji-Hoon Kim; Kyu Eun Lee; Su-Jin Kim; Jae-Kyung Won; Koung Mi Kang; Seung Hong Choi; Chul-Ho Sohn
Journal:  Neuroradiology       Date:  2016-02-05       Impact factor: 2.804

Review 2.  Selective venous sampling for primary hyperparathyroidism: how to perform an examination and interpret the results with reference to thyroid vein anatomy.

Authors:  Takayuki Yamada; Masaya Ikuno; Yasumoto Shinjo; Atsushi Hiroishi; Shoichiro Matsushita; Tsuyoshi Morimoto; Reiko Kumano; Kunihiro Yagihashi; Takuyuki Katabami
Journal:  Jpn J Radiol       Date:  2017-06-21       Impact factor: 2.374

3.  Accuracy of 2-Phase Parathyroid CT for the Preoperative Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.

Authors:  B Griffith; H Chaudhary; G Mahmood; A M Carlin; E Peterson; M Singer; S C Patel
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-10       Impact factor: 3.825

4.  Predictors of Multigland Disease in Primary Hyperparathyroidism: A Scoring System with 4D-CT Imaging and Biochemical Markers.

Authors:  A R Sepahdari; M Bahl; A Harari; H J Kim; M W Yeh; J K Hoang
Journal:  AJNR Am J Neuroradiol       Date:  2015-01-02       Impact factor: 3.825

5.  Assessment of 4DCT imaging findings of parathyroid adenomas in correlation with biochemical and histopathological findings.

Authors:  Ekim Gumeler; Olcay Kurtulan; Sevtap Arslan; Jale Karakaya; Cenk Sokmensuer; Ugur Unluturk; Kader K Oguz; Ayca Akgoz Karaosmanoglu
Journal:  Jpn J Radiol       Date:  2021-11-23       Impact factor: 2.374

6.  Prospective Validation of Two 4D-CT-Based Scoring Systems for Prediction of Multigland Disease in Primary Hyperparathyroidism.

Authors:  S Sho; M Yilma; M W Yeh; M Livhits; J X Wu; J K Hoang; A R Sepahdari
Journal:  AJNR Am J Neuroradiol       Date:  2016-09-22       Impact factor: 3.825

7.  Detection of parathyroid adenomas with multiphase 4DCT: towards a true four-dimensional technique.

Authors:  Steven Raeymaeckers; Yannick De Brucker; Tim Vanderhasselt; Nico Buls; Johan De Mey
Journal:  BMC Med Imaging       Date:  2021-04-07       Impact factor: 1.930

Review 8.  4DCT Scanning Technique for Primary Hyperparathyroidism: A Scoping Review.

Authors:  Steven Raeymaeckers; Maurizio Tosi; Johan De Mey
Journal:  Radiol Res Pract       Date:  2021-05-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.